150 related articles for article (PubMed ID: 32089245)
1. [Current advances in immunotherapy in ovarian cancer].
Le Saux O; Dubois B; Stern MH; Terme M; Tartour E; Classe JM; Chopin N; Trédan O; Caux C; Ray-Coquard I
Bull Cancer; 2020 Apr; 107(4):465-473. PubMed ID: 32089245
[TBL] [Abstract][Full Text] [Related]
2. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
Liu YL; Zamarin D
Curr Oncol Rep; 2018 Nov; 20(12):94. PubMed ID: 30421009
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.
Sau S; Alsaab HO; Bhise K; Alzhrani R; Nabil G; Iyer AK
J Control Release; 2018 Mar; 274():24-34. PubMed ID: 29391232
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Leary A; Tan D; Ledermann J
Ther Adv Med Oncol; 2021; 13():17588359211039899. PubMed ID: 34422119
[TBL] [Abstract][Full Text] [Related]
5. Cellular immunotherapy for ovarian cancer.
Cannon MJ; O'Brien TJ
Expert Opin Biol Ther; 2009 Jun; 9(6):677-88. PubMed ID: 19456205
[TBL] [Abstract][Full Text] [Related]
6. Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.
Macpherson AM; Barry SC; Ricciardelli C; Oehler MK
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32937961
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.
Palaia I; Tomao F; Sassu CM; Musacchio L; Benedetti Panici P
Onco Targets Ther; 2020; 13():6109-6129. PubMed ID: 32617007
[TBL] [Abstract][Full Text] [Related]
8. Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives.
Reverdy T; Sajous C; Péron J; Glehen O; Bakrin N; Gertych W; Lopez J; You B; Freyer G
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32854393
[TBL] [Abstract][Full Text] [Related]
9. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
[TBL] [Abstract][Full Text] [Related]
10. The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR; Coleman RL; González-Martín A; Moore KN; Colombo N; Ray-Coquard I; Pignata S
Ann Oncol; 2020 Sep; 31(9):1148-1159. PubMed ID: 32569725
[TBL] [Abstract][Full Text] [Related]
11. Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft LE; Odunsi K; Coukos G
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
[TBL] [Abstract][Full Text] [Related]
12. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.
Baci D; Bosi A; Gallazzi M; Rizzi M; Noonan DM; Poggi A; Bruno A; Mortara L
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354198
[TBL] [Abstract][Full Text] [Related]
13. Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma.
Shen J; Sun X; Zhou J
Front Oncol; 2020; 10():1263. PubMed ID: 32983962
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
15. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
Green AK; Feinberg J; Makker V
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy Advances for Epithelial Ovarian Cancer.
Hartnett EG; Knight J; Radolec M; Buckanovich RJ; Edwards RP; Vlad AM
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322601
[TBL] [Abstract][Full Text] [Related]
17. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer.
Le Saux O; Ray-Coquard I; Labidi-Galy SI
Semin Cancer Biol; 2021 Dec; 77():127-143. PubMed ID: 32931951
[TBL] [Abstract][Full Text] [Related]
18. Immuno-oncology for Gynecologic Malignancies.
How J; Patel A; Jazaeri A
Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
[TBL] [Abstract][Full Text] [Related]
19. Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Gogineni V; Morand S; Staats H; Royfman R; Devanaboyina M; Einloth K; Dever D; Stanbery L; Aaron P; Manning L; Walter A; Edelman G; Dworkin L; Nemunaitis J
J Cancer; 2021; 12(1):38-53. PubMed ID: 33391401
[TBL] [Abstract][Full Text] [Related]
20. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Färkkilä A; Gulhan DC; Casado J; Jacobson CA; Nguyen H; Kochupurakkal B; Maliga Z; Yapp C; Chen YA; Schapiro D; Zhou Y; Graham JR; Dezube BJ; Munster P; Santagata S; Garcia E; Rodig S; Lako A; Chowdhury D; Shapiro GI; Matulonis UA; Park PJ; Hautaniemi S; Sorger PK; Swisher EM; D'Andrea AD; Konstantinopoulos PA
Nat Commun; 2020 Mar; 11(1):1459. PubMed ID: 32193378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
